EP Patent
EP2363120A1 — Combinations of dimebolin and memantine
Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2011-09-07 · 15y expired
What this patent protects
A pharmaceutical combination, characterized by comprising dimebolin or a pharmaceutically acceptable salt thereof and memantine or a pharmaceutically acceptable salt thereof.
USPTO Abstract
A pharmaceutical combination, characterized by comprising dimebolin or a pharmaceutically acceptable salt thereof and memantine or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
- Nubeqa (darolutamide) · Bayer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.